arrow
Y

Young-Chul Kim

chonnam national university hwasun hospital
H指数:44
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

作者勘误:靶向SEZ6的抗体药物偶联物ABBV-706在晚期小细胞肺癌和实体瘤中的研究:一项1期临床试验

2026-06-290
OAAI
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

靶向SEZ6抗体偶联药物ABBV-706在晚期小细胞肺癌和实体瘤中的I期临床试验

2026-06-010
OAAI
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

PACIFIC-5: 在不可切除的III期NSCLC患者中巩固durvalumab的III期临床试验,同时或序贯放化疗后无进展

2025-12-070
OAAI
FGD1 splice variant as a novel biomarker for inferior clinical outcomes and development of brain and bone metastasis in clear cell renal cell carcinoma

FGD1剪接变异体作为透明细胞肾细胞癌不良临床结局及脑、骨转移发展的新型生物标志物

2025-10-010
OAAI
Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients

与阿来替尼相比,brigatinib作为克唑替尼后二线疗法在晚期间变性淋巴瘤激酶阳性非小细胞肺癌患者中的真实世界疗效。

2025-10-010
OAAI
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

Adagrasib 与多西他赛在 KRASG12C 突变非小细胞肺癌中的比较(KRYSTAL-12):一项随机、开放标签、III 期临床试验

2025-08-070
PRE
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial
2024-11-091
PRE
Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma

栖息地升级适应性治疗 (HEAT): 一项2期试验,利用放射性栖息地导向和基因组调整辐射剂量 (GARD) 优化治疗高级软组织肉瘤

2024-04-094
OAAI
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B
2023-11-019
OAAI
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data

真实世界一线阿法替尼治疗晚期EGFR突变阳性非小细胞肺癌: 更新的生存数据

2023-11-010
OAAI